Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
暂无分享,去创建一个
[1] P. Loiseau,et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation , 1989, Clinical pharmacology and therapeutics.
[2] F. Lori,et al. Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I , 1996, Journal of clinical pharmacology.
[3] B. H. Migdalof,et al. Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases , 1988, Clinical pharmacokinetics.
[4] D. Greenblatt,et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs , 1981, Clinical pharmacology and therapeutics.
[5] F. Guengerich,et al. Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. , 1995, Biochemical pharmacology.
[6] S. Imaoka,et al. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. , 1995, The Journal of pharmacology and experimental therapeutics.
[7] M. Gibaldi,et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects , 1992, Clinical pharmacology and therapeutics.
[8] J. Meinwald,et al. Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[9] D. Paton,et al. Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines) , 1985, Clinical pharmacokinetics.
[10] D. Back,et al. Metabolism of Zidovudine. , 1995, General pharmacology.
[11] A. Vickers,et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[12] J. P. Gonzalez,et al. Naltrexone , 2012, Drugs.
[13] A Rieutord,et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. , 2003, British journal of clinical pharmacology.
[14] D. Tepper,et al. Betaxolol: A New Long‐Acting Beta1‐Selective Adrenergic Blocker , 1990, Journal of clinical pharmacology.
[15] M. Max,et al. The Pharmacokinetics of Heroin in Patients with Chronic Pain , 1984, The New England journal of medicine.
[16] P. Neuvonen,et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole , 1994 .
[17] I. Fong,et al. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients , 1995, Antimicrobial agents and chemotherapy.
[18] M. Sari,et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. , 1991, Journal of medicinal chemistry.
[19] C. Campañá,et al. Clinically Significant Drug Interactions with Cyclosporin An Update , 1996, Clinical pharmacokinetics.
[20] Y. Masuda,et al. Purification and characterization of bleomycin hydrolase, which represents a new family of cysteine proteases, from rat skin. , 1996, Journal of biochemistry.
[21] D. Roden,et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.
[22] R. Post,et al. The emerging role of cytochrome P450 3A in psychopharmacology. , 1995, Journal of clinical psychopharmacology.
[23] R B Smith,et al. A pharmacokinetic drug interaction between erythromycin and triazolam. , 1986, Journal of clinical psychopharmacology.
[24] D. Hudgel,et al. Inhibition of theophylline clearance by troleandomycin. , 1977, The Journal of allergy and clinical immunology.
[25] K. Arastéh,et al. Pharmacokinetic Optimisation in the Treatment of Pneumocystis carinii Pneumonia , 1993, Clinical pharmacokinetics.
[26] M. Strolin Benedetti,et al. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. , 1994, Environmental health perspectives.
[27] V. F. Mauro. Clinical Pharmacokinetics and Practical Applications of Simvastatin , 1993, Clinical pharmacokinetics.
[28] Jouni Ahonen,et al. The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam , 1996, Anesthesia and analgesia.
[29] A. Vickers,et al. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[30] K. Lehr,et al. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. , 1990, Journal of chromatography.
[31] G. Woody,et al. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene , 1982, Clinical pharmacology and therapeutics.
[32] P. Meredith,et al. Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships , 1993, Clinical pharmacokinetics.
[33] D. Noe,et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[34] E. Leinonen,et al. Paroxetine increases serum trimipramine concentration. A report of two cases , 1995 .
[35] C. Alm,et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings , 1989, Clinical pharmacology and therapeutics.
[36] J F Steiner,et al. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride , 1996, Clinical pharmacokinetics.
[37] M. Tarbit,et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[38] L. Benet,et al. Pharmacokinetics of nicotinic acid – salicylic acid interaction , 1989, Clinical pharmacology and therapeutics.
[39] D. McTavish,et al. Fluoxetine: An Overview of its Pharmacodynamic and Pharmacokinetic Properties and Review of its Therapeutic Efficacy in Obsessive-Compulsive Disorder , 1995 .
[40] M. Snow,et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. , 1996, Biochemical pharmacology.
[41] J. Kuhlmann,et al. Nimodipine. Potential for drug-drug interactions in the elderly. , 1995, Drugs & aging.
[42] J. Longstreth,et al. Simultaneous First‐Order and Capacity‐Limited Elimination Kinetics After Oral Administration of Verapamil , 1996, Journal of clinical pharmacology.
[43] L. Kaminsky,et al. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. , 1995, Biochemical pharmacology.
[44] O. Vakkuri,et al. A cyclic isomer of 2-hydroxymelatonin: a novel metabolite of melatonin. , 1987, Endocrinology.
[45] E. Sellers,et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.
[46] F. Aoki,et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine , 1993, Clinical pharmacology and therapeutics.
[47] P. Chakravarty,et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[48] A. Poso,et al. Competitive inhibition of coumarin 7‐hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP2A6 , 1995, British journal of pharmacology.
[49] S. Spielberg,et al. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[50] A. El‐Yazigi,et al. Steady‐State Kinetics of Fluoxetine and Amitriptyline in Patients Treated with a Combination of These Drugs as Compared with Those Treated with Amitriptyline Alone , 1995, Journal of clinical pharmacology.
[51] C. King,et al. Drugs five years later: praziquantel. , 1989, Annals of internal medicine.
[52] U. Klotz,et al. Influence of Diet and Nutritional Status on Drug Metabolism , 1996, Clinical pharmacokinetics.
[53] N. Benowitz,et al. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. , 1994, The Journal of pharmacology and experimental therapeutics.
[54] R. Wills. Clinical Pharmacokinetics of Interferons , 1990, Clinical pharmacokinetics.
[55] S. Marder,et al. Clinical Perspectives of Some Neuroleptics Through Development and Application of Their Assays , 1993, Therapeutic Drug Monitoring.
[56] R. Blouin,et al. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. , 1993, British journal of clinical pharmacology.
[57] J. Harten. Overview of the Pharmacokinetics of Fluvoxamine , 1995 .
[58] L. Wienkers,et al. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[59] E. Mini,et al. Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.
[60] H. Yamazaki,et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. , 1994, Environmental health perspectives.
[61] R. N. Brogden,et al. Torasemide. An update of its pharmacological properties and therapeutic efficacy. , 1995, Drugs.
[62] R J Edwards,et al. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[63] B. K. Park,et al. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. , 1995, British journal of clinical pharmacology.
[64] J S Harmatz,et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.
[65] F. Frey,et al. Clinical Pharmacokinetics of Prednisone and Prednisolone , 1990, Clinical pharmacokinetics.
[66] L. Benet,et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.
[67] A. Fujimura,et al. Metabolites of Antihypertensive Drugs , 1991 .
[68] B. Bennett,et al. Biotransformation of organic nitrates and vascular smooth muscle cell function. , 1994, Trends in pharmacological sciences.
[69] M. Namer,et al. Age‐related difference in tamoxifen disposition , 1996, Clinical pharmacology and therapeutics.
[70] J. Kovarik,et al. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites , 1995, Antimicrobial agents and chemotherapy.
[71] M. Slevin,et al. The Clinical Pharmacology of Etoposide and Teniposide , 1987, Clinical pharmacokinetics.
[72] Matthew L. Lenz,et al. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. , 1995, American journal of hypertension.
[73] M. Schweder,et al. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. , 1996, Cancer gene therapy.
[74] G. Siest,et al. Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide. , 1995, Molecular pharmacology.
[75] F. Guengerich,et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.
[76] P. Watkins,et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.
[77] D. Roden,et al. Quinidine reduces clearance of (+)‐propranolol more than (−)‐propranolol through marked reduction in 4‐hydroxylation , 1990, Clinical pharmacology and therapeutics.
[78] P. Neuvonen,et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice , 1995, Clinical pharmacology and therapeutics.
[79] K. Marsh,et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. , 1992, British journal of clinical pharmacology.
[80] L. Bertilsson,et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.
[81] K. Simons,et al. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. , 1984, The Journal of allergy and clinical immunology.
[82] F. Guengerich. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.
[83] R. Kim,et al. Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms , 1995, Clinical pharmacology and therapeutics.
[84] M. Dudley. Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.
[85] E. Sellers. Plasma protein displacement interactions are rarely of clinical significance. , 1979, Pharmacology.
[86] J. Unadkat,et al. Clinical Pharmacokinetics of Zidovudine , 1989, Clinical pharmacokinetics.
[87] D. Greenblatt,et al. Metabolism of Drugs by Cytochrome P450 3A Isoforms , 1995, Clinical pharmacokinetics.
[88] R. Slaughter,et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin , 1995, Clinical pharmacology and therapeutics.
[89] D. H. Schroeder,et al. Carbamazepine but not valproate induces bupropion metabolism. , 1995, Journal of clinical psychopharmacology.
[90] A. Cederbaum,et al. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. , 1995, The Journal of pharmacology and experimental therapeutics.
[91] B. Huitfeldt,et al. Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. , 1986, British journal of clinical pharmacology.
[92] P. Beaune,et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. , 1996, The Journal of pharmacology and experimental therapeutics.
[93] I. Arias,et al. Multidrug resistance genes, p‐glycoprotein and the liver , 1990, Hepatology.
[94] L. Bertilsson,et al. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.
[95] F. Sallee,et al. Pharmacokinetics of Pimozide in Adults and Children with Tourette's Syndrome , 1987, Journal of clinical pharmacology.
[96] M. Relling,et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.
[97] S. Ward,et al. Clinical Pharmacokinetics in the Treatment of Tropical Diseases , 1994, Clinical pharmacokinetics.
[98] D. Back,et al. Azoles, a48 llylamines and drug metabolism , 1992 .
[99] A. Wagstaff,et al. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. , 1995 .
[100] S. Kirkesseli,et al. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects , 1995, Biopharmaceutics & drug disposition.
[101] P. Bonnabry,et al. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. , 1993, Drugs under experimental and clinical research.
[102] B. Bannwarth,et al. Clinical Pharmacokinetics of Low-Dose Pulse Methotrexate in Rheumatoid Arthritis , 1996, Clinical pharmacokinetics.
[103] R. Tukey,et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. , 1996, Biochemical pharmacology.
[104] D. Lowenthal,et al. Clinical Pharmacokinetics of Clonidine , 1988, Clinical pharmacokinetics.
[105] D E Salazar,et al. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. , 1995, Journal of clinical psychopharmacology.
[106] H. McClure,et al. In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine , 1993, Antimicrobial Agents and Chemotherapy.
[107] P. Meredith,et al. Clinical Pharmacokinetics of Prazosin — 1985 , 1985, Clinical pharmacokinetics.
[108] D. Bailey,et al. Grapefruit Juice and Drugs , 1994, Clinical pharmacokinetics.
[109] C. Bonfils,et al. Oxidative metabolism of zolpidem by human liver cytochrome P450S. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[110] P. Neuvonen,et al. Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.
[111] S. Wrighton,et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.
[112] I. Blair,et al. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[113] K. Brøsen,et al. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. , 1995, British journal of clinical pharmacology.
[114] F. Guengerich,et al. Interactions of FK506 (tacrolimus) with clinically important drugs. , 1996, Research communications in molecular pathology and pharmacology.
[115] L. Bertilsson,et al. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism , 1984, Clinical pharmacology and therapeutics.
[116] H. Breiter,et al. Pharmacokinetics of N‐acetylprocainamide in patients profiled with a stable isotope method , 1989, Clinical pharmacology and therapeutics.
[117] A. D. Rodrigues,et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[118] E. Sellers,et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity , 1993, Clinical pharmacology and therapeutics.
[119] D. Waxman,et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.
[120] J. Lin,et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[121] M. O’Connell. Pharmacokinetic and Pharmacologic Variation Between Different Estrogen Products , 1995, Journal of clinical pharmacology.
[122] K. Igarashi,et al. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. , 1995, Life sciences.
[123] J. Lynch,et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.
[124] P. Rolan. Plasma protein binding displacement interactions--why are they still regarded as clinically important? , 1994, British journal of clinical pharmacology.
[125] J. Benítez,et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population , 1995, Clinical pharmacology and therapeutics.
[126] M. Shelton,et al. Comparative Pharmacokinetics of Antiviral Nucleoside Analogues , 1993, Clinical pharmacokinetics.
[127] D A Smith,et al. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.
[128] G. Tucker,et al. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. , 1995, Biochemical pharmacology.
[129] T. Self,et al. Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism , 1992, Antimicrobial Agents and Chemotherapy.
[130] R. Tukey,et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. , 1994, Biochemical pharmacology.
[131] P. Glue,et al. Effects of felbamate on the pharmacokinetics of phenobarbital , 1995, Clinical pharmacology and therapeutics.
[132] K. Lasseter,et al. Single‐Dose and Steady‐State Pharmacokinetics of Fosinopril and Fosinoprilat in Patients with Hepatic Impairment , 1995, Journal of clinical pharmacology.
[133] H. Jick,et al. Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.
[134] Tom Chang,et al. Therapeutic Drug Monitoring of Phenytoin Rationale and Current Status , 1990, Clinical pharmacokinetics.
[135] E. M. Storch,et al. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[136] R. Hook,et al. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[137] W. Frishman,et al. Pharmacokinetic Optimisation of Therapy with β-Adrenergic Blocking Agents , 1991 .
[138] M. W. Tsang,et al. Metabolism of haloperidol: clinical implications and unanswered questions. , 1994, Journal of clinical psychopharmacology.
[139] K. Midha,et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. , 1996, Journal of clinical psychopharmacology.
[140] H. Yamazaki,et al. Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes , 1996 .
[141] F. Gonzalez,et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.
[142] R A Mueller,et al. Pharmacokinetics of methylphenidate in man, rat and monkey. , 1983, The Journal of pharmacology and experimental therapeutics.
[143] S. Wrighton,et al. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. , 1989, Archives of biochemistry and biophysics.
[144] S. Sindrup,et al. The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.
[145] A. D. Rodrigues,et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.
[146] R. Schoenwald,et al. Furosemide (Frusemide) A Pharmacokinetic/Pharmacodynamic Review (Part I) , 1990, Clinical pharmacokinetics.
[147] L. Balant,et al. Clinical Pharmacokinetics of Clomipramine , 1991, Clinical pharmacokinetics.
[148] S. Sonne,et al. Venlafaxine: A Structurally Unique and Novel Antidepressant , 1995, The Annals of pharmacotherapy.
[149] D. Bailey,et al. Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin , 1993, Clinical pharmacology and therapeutics.
[150] F. Jamali,et al. Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.
[151] B. Flouvat,et al. Clinical Pharmacokinetics of Lansoprazole , 1995, Clinical pharmacokinetics.
[152] S. Garattini,et al. Kinetic and pharmacological studies on estazolam in mice and man. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.
[153] D. Greenblatt,et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. , 1995, Journal of clinical psychopharmacology.
[154] J. Horn,et al. Glipizide pharmacokinetics in young and elderly volunteers. , 1988, Clinical pharmacy.
[155] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[156] K. Goa,et al. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. , 1995, Drugs.
[157] R. Levy. Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.
[158] R. Branch,et al. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation , 1985, Clinical pharmacology and therapeutics.
[159] L. Dubé,et al. Effect of Zileuton on Theophylline Pharmacokinetics , 1995, Clinical pharmacokinetics.
[160] B. K. Park,et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.
[161] F. Guengerich,et al. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. , 1993, Drug Metabolism And Disposition.
[162] S. Weinreb,et al. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. , 1986, Toxicology and applied pharmacology.
[163] G. Smith,et al. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[164] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.
[165] J. Leonard,et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. , 1998, British journal of clinical pharmacology.
[166] D. Kim,et al. Identification of urinary metabolites of pyrilamine after oral administration to man. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[167] P. Neuvonen,et al. Diltiazem enhances the effects of triazolam by inhibiting its metabolism , 1996, Clinical pharmacology and therapeutics.
[168] R. Polk,et al. Pharmacokinetic Drug Interactions with Antimicrobial Agents , 1993, Clinical pharmacokinetics.
[169] A. Hiller,et al. A potentially hazardous interaction between erythromycin and midazolam , 1993 .
[170] E. Perucca,et al. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. , 1994, Therapeutic drug monitoring.
[171] M. Cayen,et al. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations , 1995, Clinical pharmacology and therapeutics.
[172] L. Bertilsson,et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol , 1996, Clinical pharmacology and therapeutics.
[173] R. Baldessarini,et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. , 1994, The American journal of psychiatry.
[174] J. Quion,et al. Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.
[175] D. Greenblatt,et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. , 1996, Journal of clinical psychopharmacology.
[176] W. Shen. Cytochrome P450 Monooxygenases and Interactions of Psychotropic Drugs: A Five-Year Update , 1995, International journal of psychiatry in medicine.
[177] P. Salvà,et al. Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem , 1995, Clinical pharmacokinetics.
[178] S. Nelson,et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. , 1993, Biochemical pharmacology.
[179] P. Glue,et al. Psychiatry, psychopharmacology and P‐450s , 1996 .
[180] D. Greenblatt,et al. In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction , 1994, Journal of clinical pharmacology.
[181] U. Tröger,et al. Influence of Endogenous and Exogenous Effectors on the Pharmacokinetics of Theophylline , 1995, Clinical pharmacokinetics.
[182] Susan E. Wilson,et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174 , 1996, Clinical pharmacology and therapeutics.
[183] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[184] P. Maurel,et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[185] G. Bellward,et al. Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex. , 1995, Drug Metabolism And Disposition.
[186] A. Somogyi,et al. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. , 1994, The Journal of pharmacology and experimental therapeutics.
[187] J. Miners,et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. , 1994, British journal of clinical pharmacology.
[188] S. Piscitelli,et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer , 1994, Cancer.
[189] P. Rolan. Pharmacokinetics of New Antiherpetic Agents , 1995, Clinical pharmacokinetics.
[190] A. D. Rodrigues,et al. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[191] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[192] F. Gonzalez,et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. , 1995, Pharmacogenetics.
[193] T. Kronbach,et al. Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.
[194] A. Mooradian,et al. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. , 1988, Clinical pharmacokinetics.
[195] F. Gonzalez,et al. Molecular genetics of the debrisoquin‐sparteine polymorphism , 1991, Clinical pharmacology and therapeutics.
[196] D. Back,et al. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.
[197] L. Wiseman,et al. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. , 1994, Drugs.
[198] G. Blaschke,et al. Stereoselectivity of the in vitro metabolism of thalidomide , 1994 .
[199] K. Chiba,et al. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. , 1994, The Journal of pharmacology and experimental therapeutics.
[200] P. McNamara,et al. Age and propranolol stereoselective disposition in humans , 1992, Clinical pharmacology and therapeutics.
[201] E. Kharasch,et al. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers , 1996, Clinical pharmacology and therapeutics.
[202] S. Wrighton,et al. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.
[203] M. Eichelbaum,et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.
[204] F. Gonzalez,et al. The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.
[205] A. Troendle,et al. Pharmacokinetics of fluvastatin and specific drug interactions. , 1993, American journal of hypertension.
[206] W. Trager,et al. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[207] S. Otton,et al. Sparteine oxidation is practically abolished in quinidine-treated patients. , 1986, British journal of clinical pharmacology.
[208] G. Tucker,et al. Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.
[209] L. Bertilsson,et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[210] U. Stephan,et al. Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues , 1989, Clinical pharmacokinetics.
[211] A. Somogyi,et al. Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene , 1986, Clinical pharmacology and therapeutics.
[212] P. Neuvonen,et al. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.
[213] C. Bonfils,et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[214] E. Sellers,et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone , 1993, Clinical pharmacology and therapeutics.
[215] E. Skjelbo,et al. Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.
[216] Pharmacokinetics of Pravastatin in Elderly versus Young Men and Women , 1993, The Annals of pharmacotherapy.
[217] J. Secor,et al. The Effect of Route of Administration on the Cimetidine‐Theophylline Drug Interaction , 1989, Journal of clinical pharmacology.
[218] W. Campbell. Ivermectin, an antiparasitic agent , 1993, Medicinal research reviews.
[219] M. Eichelbaum,et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose‐dependent clearance, and interaction with amiodarone , 1994, Clinical pharmacology and therapeutics.
[220] D. Greenblatt,et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.
[221] E. Kharasch,et al. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo , 1995, Clinical pharmacology and therapeutics.
[222] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. , 1985, Gastroenterology.
[223] L. Danziger,et al. Central Nervous System Toxicity Associated With Meperidine Use in Hepatic Disease , 1994, Pharmacotherapy.
[224] D. Back,et al. Pharmacokinetic Drug Interactions with Oral Contraceptives , 1990, Clinical pharmacokinetics.
[225] P. Meffin,et al. Clinical Pharmacokinetics Pethidine , 1978, Clinical pharmacokinetics.
[226] E. Hartshorn,et al. Adverse Effects and Drug Interactions Associated with Fluoxetine Therapy , 1991, DICP : the annals of pharmacotherapy.
[227] F. Macciardi,et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. , 1996, Pharmacopsychiatry.
[228] Ethosuximide kinetics: Possible interaction with valproic acid , 1982, Clinical pharmacology and therapeutics.
[229] D. Greenblatt,et al. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.
[230] M. Relling,et al. Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.
[231] D. Roden,et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. , 1987, Circulation.
[232] J. L. Russell,et al. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. , 1996, Journal of clinical psychopharmacology.
[233] J. Brockmöller,et al. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[234] F. Guengerich,et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[235] L. Bertilsson,et al. Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service , 1994, Therapeutic drug monitoring.
[236] S. Lundgren,et al. Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. , 1988, Journal of steroid biochemistry.
[237] M. Eichelbaum,et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.
[238] E. Bailey,et al. Ofloxacin Clinical Pharmacokinetics , 1992, Clinical pharmacokinetics.
[239] M. Gombert,et al. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. , 1987, JAMA.
[240] D. Kroetz,et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.
[241] R. Woosley,et al. Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.
[242] W. Kalow,et al. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.
[243] M. T. Donato,et al. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[244] N. Hagen,et al. Steady‐State Pharmacokinetics of Hydromorphone and Hydromorphone‐3‐Glucuronide in Cancer Patients After Immediate and Controlled‐Release Hydromorphone , 1995, Journal of clinical pharmacology.
[245] S. Clarke,et al. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[246] R. Dahlqvist,et al. Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.
[247] R. Woosley,et al. A Metabolic Interaction Between Clarithromycin and Pimozide May Result in Cardiac Toxicity , 1996 .
[248] I. M. Young,et al. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. , 1985, The Journal of clinical endocrinology and metabolism.
[249] K. Brøsen,et al. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.
[250] R. N. Brogden,et al. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. , 1992, Drugs.
[251] E. Perucca,et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers , 1994, Clinical pharmacology and therapeutics.
[252] G. Béréziat,et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. , 1992, The Journal of pharmacology and experimental therapeutics.
[253] L. Bertilsson,et al. E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.
[254] P. Beaune,et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. , 1996, Chemical research in toxicology.
[255] S. Ward,et al. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. , 1995, British journal of clinical pharmacology.
[256] T. Bjornsson,et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans , 1995, Clinical pharmacology and therapeutics.
[257] L. Bertilsson,et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. , 1994, British journal of clinical pharmacology.
[258] L. Benet,et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.
[259] M. Eichelbaum,et al. Is there a genetic factor in flecainide toxicity? , 1988, BMJ.
[260] G. Tucker,et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. , 1992, British journal of clinical pharmacology.
[261] M. Bialer. Comparative Pharmacokinetics of the Newer Antiepileptic Drugs , 1993, Clinical pharmacokinetics.
[262] F. Donati,et al. Early Pharmacokinetics of Midazolam , 1995 .
[263] P. Neuvonen,et al. Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin , 1996, Epilepsia.
[264] G. Tucker,et al. The Polymorphic Oxidation of β-Adrenoceptor Antagonists , 1986 .
[265] P. Watkins,et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol , 1992, Clinical pharmacology and therapeutics.
[266] J. Gabrielsson,et al. Pharmacokinetics of Quinacrine after Intrapleural Instillation in Rabbits and Man , 1989, The Journal of pharmacy and pharmacology.
[267] E. Perucca,et al. Phenobarbital induces the 2-hydroxylation of desipramine. , 1996, Therapeutic drug monitoring.
[268] W. Jusko,et al. Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.
[269] C. W. Fisher,et al. The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. , 1995, Archives of biochemistry and biophysics.
[270] R. Kato,et al. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. , 1994, Pharmacogenetics.
[271] R. Tukey,et al. Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[272] M. Ingelman-Sundberg,et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.
[273] A. Melander,et al. Slow Elimination of Glyburide in NIDDM Subjects , 1994, Diabetes Care.
[274] K. Simons,et al. An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects. , 1986, The Journal of allergy and clinical immunology.
[275] K. Chiba,et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.
[276] R. Miller,et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[277] L. Bertilsson,et al. d-Propoxyphene is a Potent Inhibitor of Debrisoquine, but Not S-Mephenytoin 4‐Hydroxylation In Vivo , 1990, Therapeutic drug monitoring.
[278] A. Favero,et al. Ondansetron Clinical Pharmacokinetics , 1995, Clinical pharmacokinetics.
[279] S. Wrighton,et al. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.
[280] J. Rask-Madsen,et al. Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.
[281] B. Burlew,et al. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[282] C. Bahr,et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype , 1991, Clinical pharmacology and therapeutics.
[283] J. Turgeon,et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin , 1996, Clinical pharmacology and therapeutics.
[284] T. Aoyama,et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.
[285] C. Funck-Brentano,et al. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. , 1993, British journal of clinical pharmacology.
[286] P. Watkins,et al. The erythromycin breath test predicts the clearance of midazolam , 1995, Clinical pharmacology and therapeutics.
[287] Wojciech Piekoszewski,et al. Pharmacokinetics of tacrolimus in liver transplant patients , 1995, Clinical pharmacology and therapeutics.
[288] K. Lauritsen,et al. Clinical pharmacolinetics of drugs used in the treatment of gastrointestinal diseases. I , 1990 .
[289] D. Koop. Oxidative and reductive metabolism by cytochrome P450 2E1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[290] N. White,et al. Pharmacokinetics of Quinine, Chloroquine and Amodiaquine , 1996, Clinical pharmacokinetics.
[291] J. Estes. Clinical Pharmacokinetics of Heparin , 1980, Clinical pharmacokinetics.
[292] J. Feighner,et al. Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.
[293] E. Hussey,et al. Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine , 1995, Journal of clinical pharmacology.
[294] D. Peters,et al. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. , 1995, Drugs.
[295] G. Granneman,et al. Effects of 2 Quinolone Antibacterials, Temafloxacin and Enoxacin, on Theophylline Pharmacokinetics , 1992, Clinical pharmacokinetics.
[296] L. Shargel,et al. Effect of phenobarbital pretreatment on the plasma and urinary levels of (-)-alpha-acetylmethadol and its metabolites. , 1985, Journal of pharmaceutical sciences.
[297] B. K. Park,et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. , 1994, British journal of clinical pharmacology.
[298] U. Christians,et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[299] G. Drusano,et al. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate , 1989, Antimicrobial Agents and Chemotherapy.
[300] R. Nayak,et al. Pharmacokinetics of Bepridil and Two of its Metabolites in Patients With End‐Stage Renal Disease , 1995, Journal of clinical pharmacology.
[301] L. Ereshefsky,et al. Antidepressant Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.
[302] R. Woestenborghs,et al. Dose‐proportionality, bioavailability, and steady‐state kinetics of astemizole in man , 1986 .
[303] J. Sommadossi. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. , 1995, The Journal of infectious diseases.
[304] H. Thijssen,et al. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics , 1993, British journal of pharmacology.
[305] S. Loft,et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. , 1995, British journal of clinical pharmacology.
[306] J. Wierda,et al. Clinical Pharmacokinetics of Neuromuscular Blocking Drugs , 1992, Clinical pharmacokinetics.
[307] D. Back,et al. Theophylline metabolism in human liver microsomes: inhibition studies. , 1996, The Journal of pharmacology and experimental therapeutics.
[308] Y. Fujii‐Kuriyama,et al. Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. , 1996, Archives of biochemistry and biophysics.
[309] I. Yamamoto,et al. Recent advances in the metabolism of cannabinoids. , 1995, The international journal of biochemistry & cell biology.
[310] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[311] E. Kharasch,et al. Identification of Cytochrome P450 2E1 as the Predominant Enzyme Catalyzing Human Liver Microsomal Defluorination of Sevoflurane, Isoflurane, and Methoxyflurane , 1993, Anesthesiology.
[312] X. J. Zhou,et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.
[313] C. Cerniglia,et al. Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans , 1996, Applied and environmental microbiology.
[314] S. Ōmura,et al. Inhibition of Sporulation by Cerulenin and Its Reversion by Exogenous Fatty Acids in Saccharomyces cerevisiae , 1976, Antimicrobial Agents and Chemotherapy.
[315] T. Mettang,et al. Propafenone in a usual dose produces severe side‐effects: the impact of genetically determined metabolic status on drug therapy , 1995, Journal of internal medicine.
[316] M. Green,et al. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[317] J. Prieto,et al. Small intestinal sulphoxidation of albendazole. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[318] T. Leemann,et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin , 1995, Clinical pharmacology and therapeutics.
[319] D. Kroetz,et al. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide , 1993, Clinical pharmacology and therapeutics.
[320] D. Lowe,et al. Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. , 1992, Methods and findings in experimental and clinical pharmacology.
[321] Y. Horsmans,et al. Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines , 1995, Clinical pharmacokinetics.
[322] Bramahn . Singh,et al. Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine. , 1990, American heart journal.
[323] D D Shen,et al. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[324] R. Mailman,et al. Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[325] K. Fotherby. Levonorgestrel. Clinical pharmacokinetics. , 1995, Clinical pharmacokinetics.
[326] T. Someya,et al. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. , 1995, Journal of clinical psychopharmacology.
[327] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[328] B. K. Park,et al. Clinical Pharmacokinetics of Tacrine , 1995, Clinical pharmacokinetics.
[329] Griffin Jp,et al. Interactions with drugs used in the treatment of depressive illness. , 1995 .
[330] S. Symchowicz,et al. Absorption, excretion and urinary metabolic pattern of 3 H-albuterol aerosol in man. , 1972, Xenobiotica; the fate of foreign compounds in biological systems.
[331] W. Leader,et al. Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.
[332] D. Greenblatt. Clinical Pharmacokinetics of Oxazepam and Lorazepam , 1981, Clinical pharmacokinetics.
[333] A. Lindholm,et al. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. , 1990, Pharmacology & toxicology.
[334] S. Spinler,et al. Possible inhibition of hepatic metabolism of quinidine by erythromycin , 1995, Clinical pharmacology and therapeutics.
[335] R. Day,et al. Stereoselective disposition of ibuprofen enantiomers in infants. , 1985 .
[336] A. Boer,et al. Drug Interactions With Thrombolytic Agents , 1995 .
[337] T. Pincus,et al. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine , 1996, Clinical pharmacology and therapeutics.
[338] E. Kharasch,et al. Clinical enflurane metabolism by cytochrome P450 2E1 , 1994 .
[339] M. Byerly,et al. Pharmacokinetics of clozapine and risperidone: a review of recent literature. , 1996, Journal of clinical psychopharmacology.
[340] B. Burchell,et al. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. , 1993, Molecular pharmacology.
[341] R. Yatscoff,et al. Rapamycin: Distribution, Pharmacokinetics, and Therapeutic Range Investigations , 1995, Therapeutic drug monitoring.
[342] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[343] S. Nattel,et al. The Pharmacokinetics of Lignocaine and β-Adrenoceptor Antagonists in Patients with Acute Myocardial Infarction , 1987, Clinical pharmacokinetics.
[344] A. Gaber,et al. Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole. , 1996, Transplantation.
[345] Bramahn . Singh,et al. Acebutolol: A Review of its Pharmacology, Pharmacokinetics, Clinical Uses, and Adverse Effects , 1982, Pharmacotherapy.
[346] T Ishizaki,et al. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. , 1995, British journal of clinical pharmacology.
[347] R. Martini,et al. Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. , 1993, Archives of biochemistry and biophysics.
[348] A. Bedding,et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. , 1994, British journal of clinical pharmacology.
[349] Hara,et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. , 1995, Biochemical pharmacology.
[350] D. W. Robin,et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. , 1996, British journal of clinical pharmacology.
[351] S. Hallam,et al. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. , 1995, Biochemical pharmacology.
[352] Michael E. Klepser,et al. Clinical Pharmacokinetics of Newer Cephalosporins , 1995, Clinical pharmacokinetics.
[353] S. Imaoka,et al. Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. , 1995, The Journal of pharmacology and experimental therapeutics.
[354] M. Rowland,et al. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.
[355] I. Kanfer,et al. Steady State Pharmacokinetics and Dose‐Proportionality of Phenylpropanolamine in Healthy Subjects , 1990, Journal of clinical pharmacology.
[356] D. Faulds,et al. Cetirizine : A Reappraisal of its Pharmacological Properties and Therapeutic Use in Selected Allergic Disorders. , 1993, Drugs.
[357] J. Unadkat,et al. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[358] A. K. Scott. Sumatriptan Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.
[359] H K Kroemer,et al. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.
[360] K. Simons,et al. The pharmacokinetics and antihistaminic effects of brompheniramine. , 1982, The Journal of allergy and clinical immunology.
[361] J S Harmatz,et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.
[362] A. Metz,et al. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. , 1990, International Clinical Psychopharmacology.
[363] Y. Funae,et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[364] R. N. Brogden,et al. Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. , 1995, Drugs.
[365] D. Helmeste,et al. Paroxetine shifts imipramine metabolism , 1996, Psychiatry Research.
[366] W. Jaeger,et al. Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.
[367] R. Barbhaiya,et al. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. , 1996, Journal of clinical psychopharmacology.
[368] A. Caputi,et al. Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. , 1994, Pharmacological research.
[369] E. Sellers,et al. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. , 1995, Journal of clinical psychopharmacology.
[370] J. Saurat,et al. Metabolism of oral 9-cis-retinoic acid in the human. Identification of 9-cis-retinoyl-beta-glucuronide and 9-cis-4-oxo-retinoyl-beta-glucuronide as urinary metabolites. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[371] D. Gottschall,et al. The metabolism of benzimidazole anthelmintics. , 1990, Parasitology today.
[372] A. Artru,et al. Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation , 1995 .
[373] K. Otani,et al. Inhibition of Trazodone Metabolism by Thioridazine in Humans , 1995, Therapeutic drug monitoring.
[374] S. Nelson,et al. Inhibition and induction of cytochrome P4502E1‐catalyzed oxidation by isoniazid in humans , 1993, Clinical pharmacology and therapeutics.
[375] T. Self,et al. Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. , 1996, The Journal of family practice.
[376] B. Sadler,et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine , 1996, Clinical pharmacology and therapeutics.
[377] G. Tucker,et al. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. , 1994, Carcinogenesis.
[378] M. Jann,et al. Intra‐ and Interethnic Variability in Reduced Haloperidol to Haloperidol Ratios , 1995, Journal of clinical pharmacology.
[379] A. Breckenridge,et al. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. , 1990, British journal of clinical pharmacology.
[380] S. Strom,et al. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. , 1996, Molecular pharmacology.
[381] C. Gleiter,et al. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. , 1994, British journal of clinical pharmacology.
[382] P. Neuvonen,et al. Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. , 1996, Therapeutic drug monitoring.
[383] Thomas M. Ludden,et al. Pharmacokinetics of Quinidine in Male Patients , 1992, Clinical pharmacokinetics.
[384] P. Neuvonen,et al. Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. , 1996, Pharmacology & toxicology.
[385] W J Jusko,et al. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. , 1988, Journal of clinical psychopharmacology.
[386] T. Shimada,et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.
[387] M. Holdiness,et al. Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.
[388] K. Otani,et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.
[389] T. Vree,et al. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. , 1993, British journal of clinical pharmacology.
[390] G. Bertschy,et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. , 1995, Pharmacological research.
[391] D. Bailey,et al. Erythromycin‐felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice , 1996, Clinical pharmacology and therapeutics.
[392] A. Peer,et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects , 1993, Clinical pharmacology and therapeutics.
[393] S. Piscitelli,et al. Clinical Pharmacokinetics of Metronidazole and Other Nitroimidazole Anti-Infectives , 1992, Clinical pharmacokinetics.
[394] M. E. Ward,et al. Clinical Pharmacokinetics of Lithium , 1994, Journal of clinical pharmacology.
[395] G. Macphee,et al. Clinical Pharmacokinetics and Kinetic-Dynamic Relationships of Dilevalol and Labetalol , 1991, Clinical pharmacokinetics.
[396] R. Cutler,et al. Flucytosine kinetics in subjects with normal and impaired renal function , 1978, Clinical pharmacology and therapeutics.
[397] D. Kroetz,et al. Carbamazepine‐Valnoctamide Interaction in Epileptic Patients: In Vitro/In Vivo Correlation , 1993, Epilepsia.
[398] S. Wrighton,et al. In vitro-in vivo correlations of human (S)-nicotine metabolism. , 1995, Biochemical pharmacology.
[399] J. Brockmöller,et al. Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.
[400] B. Lacarelle,et al. Glucuronidation of Propofol in Microsomal Fractions from Various Tissues and Species Including Humans: Effect of Different Drugs , 1995, Anesthesia and analgesia.
[401] D. Waxman,et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.
[402] U. Klotz,et al. Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.
[403] P. Beaune,et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.
[404] G R Wilkinson,et al. Clearance approaches in pharmacology. , 1987, Pharmacological reviews.
[405] P. Thomas,et al. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. , 1996, Drug Metabolism And Disposition.
[406] Robert B. Diasio,et al. Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.
[407] K. Midha,et al. N(+)-glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.
[408] Kaoru Kobayashi,et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. , 1995, British journal of clinical pharmacology.
[409] T. Baillie,et al. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. , 1995, Biochemistry.
[410] R. Rahmani,et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism , 1993, Fundamental & clinical pharmacology.
[411] M. J. Coon,et al. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. , 1996, Molecular pharmacology.
[412] Devane Cl. Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents , 1994 .
[413] R. Reder,et al. Pharmacokinetic‐pharmacodynamic relationships of controlled‐release oxycodone , 1996, Clinical pharmacology and therapeutics.
[414] N. Benowitz,et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects , 1981, Clinical pharmacology and therapeutics.
[415] F. Simons,et al. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. , 1995, The Journal of allergy and clinical immunology.
[416] L. Pendyala,et al. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[417] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[418] L. Ereshefsky,et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review. , 1988, Clinical chemistry.
[419] L. Bertilsson,et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.
[420] K. Midha,et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine , 1996, European Journal of Clinical Pharmacology.
[421] E. Ette,et al. Ivermectin: A Long-Acting Microfilaricidal Agent , 1990, DICP : the annals of pharmacotherapy.
[422] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[423] X. J. Zhou,et al. Pharmacokinetics and metabolism of vinca alkaloids. , 1993, Cancer surveys.
[424] G. Tucker,et al. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. , 1984, British journal of clinical pharmacology.
[425] H K Kroemer,et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. , 1991, The Journal of pharmacology and experimental therapeutics.
[426] R. Farinotti,et al. Clinical Pharmacokinetics and Metabolism of Chloroquine , 1996, Clinical pharmacokinetics.
[427] J. Conte. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. , 1991, The Journal of infectious diseases.
[428] Yuan Zhang,et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. , 1992, Pharmacogenetics.
[429] A. Parkinson,et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. , 1994, Carcinogenesis.
[430] T. Kronbach,et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.
[431] B. Rochat,et al. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror , 1995, International clinical psychopharmacology.
[432] D. Debruyne,et al. Clinical Pharmacokinetics of Fluconazole , 1993, Clinical pharmacokinetics.
[433] U. Christians,et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. , 1996, Pharmacology.
[434] J. Goldzieher,et al. Pharmacokinetics of ethinyl estradiol and mestranol. , 1990, American journal of obstetrics and gynecology.
[435] R. Woosley,et al. Clinical Pharmacokinetics of Disopyramide , 1986, Clinical pharmacokinetics.
[436] J. Rotschafer,et al. Clinical Pharmacokinetics of Ciprofloxacin , 1990, Clinical pharmacokinetics.
[437] J. Mckenney. Lovastatin: a new cholesterol-lowering agent. , 1988, Clinical Pharmacist.
[438] J. Goldstein,et al. Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.
[439] K. Brøsen,et al. First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.
[440] S. Schenker,et al. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. , 1977, Gastroenterology.
[441] D. Bateman,et al. The pharmacokinetics of metoclopramide in man with observations in the dog. , 1980, British journal of clinical pharmacology.
[442] F. Aoki,et al. Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. , 1995, British journal of clinical pharmacology.
[443] K. Campagna,et al. Pharmacokinetics and Dialyzability of Sulindac and Metabolites in Patients with End‐Stage Renal Failure , 1993, Journal of clinical pharmacology.
[444] O. Wiborg,et al. Steady‐state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism , 1996, Clinical pharmacology and therapeutics.
[445] A. Okey. Enzyme induction in the cytochrome P-450 system. , 1990, Pharmacology & therapeutics.
[446] J. Gorrod,et al. Determination of isomeric N-oxide metabolites of some substituted 2,4-diaminopyrimidines by reversed-phase ion-pair high-performance liquid chromatography. , 1993, Journal of chromatography.
[447] M. Barry,et al. Enzyme induction and inhibition. , 1990, Pharmacology & therapeutics.
[448] K. Chiba,et al. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. , 1993, The Journal of pharmacology and experimental therapeutics.
[449] J. Miners,et al. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. , 1996, General pharmacology.
[450] B. Sallustio,et al. Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. , 1995, Drug Metabolism And Disposition.
[451] J. Miners,et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.
[452] Y. Horsmans,et al. Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. , 1993, Pharmacological research.
[453] H. El-Attar,et al. Pharmacokinetics of Antituberculosis Drugs in Patients , 1987, Journal of clinical pharmacology.
[454] T. Kronbach,et al. In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone , 1989, Clinical pharmacology and therapeutics.
[455] P. Beaune,et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 , 1990 .
[456] D. Greenblatt,et al. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. , 1993, Pharmacology.
[457] R. Bergstrom,et al. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction , 1992, Clinical pharmacology and therapeutics.
[458] R. N. Brogden,et al. Mefloquine , 1993, Drugs.
[459] R. Benton,et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram , 1996, Clinical pharmacology and therapeutics.
[460] M. Jacobson,et al. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS‐related cytomegalovirus retinitis , 1995, Clinical pharmacology and therapeutics.
[461] P. Lundborg,et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.
[462] F. Guengerich,et al. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[463] G. Cheymol,et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients , 1990, Clinical pharmacology and therapeutics.
[464] C. Eap,et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2‐sulfoxide, thioridazine 2‐sulfone, and thioridazine 5‐sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin , 1996, Clinical pharmacology and therapeutics.
[465] W. Colburn,et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain , 1987, Clinical pharmacology and therapeutics.
[466] R. Robson. The effects of quinolones on xanthine pharmacokinetics. , 1992, The American journal of medicine.
[467] D. Greenblatt,et al. Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.
[468] D. Svinarov,et al. Valproic Acid—Carbamazepine Interaction: Is Valproic Acid a Selective Inhibitor of Epoxide Hydrolase? , 1993, Therapeutic drug monitoring.
[469] P. Kroboth,et al. Pharmacokinetics of the Newer Benzodiazepines , 1989, Clinical pharmacokinetics.
[470] F. Jamali,et al. Clinical Pharmacokinetics of Ketorolac Tromethamine , 1992, Clinical pharmacokinetics.
[471] D. Back,et al. Zalcitabine (ddC) Phosphorylation and Drug Interactions , 1995 .
[472] G. Houin,et al. Clinical Pharmacokinetics of Doxycycline and Minocycline , 1988, Clinical pharmacokinetics.
[473] J. Mørland,et al. Carisoprodol Elimination in Humans , 1994, Therapeutic drug monitoring.
[474] R. D. De Abreu,et al. Metabolism of Intravenously Administered High‐Dose 6‐Mercaptopurine with and without Allopurinol Treatment in Patients with Non‐Hodgkin Lymphoma , 1996, Journal of pediatric hematology/oncology.
[475] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[476] H. Zhou,et al. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. , 1996, British journal of clinical pharmacology.
[477] D. Back,et al. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. , 1994, Biochemical pharmacology.
[478] Dominic P. Williams,et al. Metabolism and bioactivation of clozapine by human liver in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.
[479] M. Antonaccio,et al. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. , 1990, The American journal of cardiology.
[480] D. Nicolau,et al. Lomefloxacin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.
[481] J. C. Martin,et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. , 1995, The Journal of infectious diseases.
[482] K. Petersen. Omeprazole and the cytochrome P450 system , 1995 .
[483] P. P. Rop,et al. Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. , 1994, Journal of chromatography. B, Biomedical applications.
[484] J. Montaner,et al. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[485] D. Westerlund,et al. Clinical Pharmacokinetics of Co-Trimazine , 1986, Clinical pharmacokinetics.
[486] J. Kovarik,et al. Dose‐proportional pharmacokinetics of terbinafine and its N‐demethylated metabolite in healthy volunteers , 1992, The British journal of dermatology.
[487] M. Relling,et al. Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.
[488] D. Morris,et al. Azithromycin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.
[489] R. Branch,et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.
[490] F. Guengerich,et al. Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.
[491] T. Buronfosse,et al. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[492] D. McTavish,et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. , 1995, Drugs.
[493] D. Breimer,et al. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. , 1991, British journal of clinical pharmacology.
[494] R. Heel,et al. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. , 1992, Drugs.
[495] A. Breckenridge,et al. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. , 1984, British journal of clinical pharmacology.
[496] A. Wood,et al. Interethnic difference in omeprazole's inhibition of diazepam metabolism , 1995, Clinical pharmacology and therapeutics.
[497] T. Inaba. Cocaine: pharmacokinetics and biotransformation in man. , 1989, Canadian journal of physiology and pharmacology.
[498] R. Glazer,et al. Regulation of K Channel Expression and Cardiac Repolarization in the Rabbit Heart by Sex Steroid Hormones , 1996 .
[499] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[500] J. Robert,et al. Pharmacokinetics and metabolism of anthracyclines. , 1993, Cancer surveys.
[501] F. Balis,et al. Clinical Pharmacokinetics of Commonly Used Anticancer Drugs , 1983, Clinical pharmacokinetics.
[502] W. Maul,et al. The pharmacokinetics of clotrimazole 14C. , 1974, Postgraduate medical journal.
[503] I. Wainer,et al. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. , 1996, Journal of chromatography. B, Biomedical applications.
[504] D. Greenblatt,et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam , 1992, Clinical pharmacology and therapeutics.
[505] R. Ramsay,et al. Pharmacokinetics and safety of lamotrigine (Lamictal®) in patients with epilepsy , 1991, Epilepsy Research.
[506] A G Renwick,et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine , 1993, Clinical pharmacology and therapeutics.
[507] S. Ziccone,et al. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. , 1986, British journal of clinical pharmacology.
[508] D. McTavish,et al. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Acute and Chronic Pain States , 2012 .
[509] R. Wallace,,et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. , 1995, The Journal of infectious diseases.
[510] T. Henthorn,et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.
[511] F. Guengerich,et al. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. , 1992, Anesthesiology.
[512] D. Roden,et al. Drug therapy. Tocainide. , 1986, The New England journal of medicine.
[513] F. Guengerich,et al. Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation , 1996, Anesthesia and analgesia.
[514] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[515] M. Eichelbaum,et al. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. , 1991, Molecular pharmacology.
[516] R. Davis,et al. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. , 1994, Drugs.
[517] G. Pacifici,et al. Interindividual variability in the N-sulphation of desipramine in human liver and platelets. , 1992, British journal of clinical pharmacology.
[518] D. Anderson,et al. Metabolism of 14C-estazolam in dogs and humans. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.
[519] J. Wierda,et al. Pharmacokinetics and Neuromuscular Blocking Effects of Atracurium Besylate and Two of Its Metabolites in Patients with Normal and Impaired Renal Function , 1990, Clinical pharmacokinetics.
[520] D. Breimer,et al. Clinical Pharmacokinetics of Hypnotics , 1977, Clinical pharmacokinetics.
[521] T Ishizaki,et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism , 1996, Clinical pharmacology and therapeutics.
[522] P. Andersson,et al. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[523] F. Guengerich,et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.
[524] A. Freiburghaus,et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. , 1995, British journal of clinical pharmacology.
[525] P. Chaikin,et al. Pharmacokinetic and Pharmacodynamic Evaluation of Warfarin and Nefazodone Coadministration in Healthy Subjects , 1995, Journal of clinical pharmacology.
[526] R. Oberbauer,et al. Pharmacokinetics of Indomethacin in the Elderly , 1993, Clinical pharmacokinetics.
[527] L. Bertilsson,et al. Polymorphic Drug Oxidation , 1996 .
[528] W. E. Fann,et al. Multiple‐dose doxepin kinetics in depressed patients , 1983, Clinical pharmacology and therapeutics.
[529] C. Lieber,et al. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. , 1989, Archives of biochemistry and biophysics.
[530] H. Gallis,et al. Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.
[531] G. Koren,et al. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). , 1993, Life sciences.
[532] Y. Moriwaki,et al. In vitro and in vivo study on the conversion of allopurinol and pyrazinamide. , 1994, Advances in experimental medicine and biology.
[533] Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.
[534] T. Haley. Physical and biological properties of pyrilamine. , 1983, Journal of pharmaceutical sciences.
[535] W. Trager,et al. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[536] Y. Fukui,et al. Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. , 1996, Alcoholism, clinical and experimental research.
[537] W. Wagner,et al. Fluvoxamine. A review of global drug-drug interaction data. , 1995, Clinical pharmacokinetics.
[538] K. Bühring,et al. Basic Pharmacokinetics of Bisoprolol, a New Highly Beta1‐selective Adrenoceptor Antagonist , 1986, Journal of clinical pharmacology.
[539] M. Eichelbaum,et al. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. , 1995, British journal of clinical pharmacology.
[540] G. Tucker,et al. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.
[541] J S Harmatz,et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.
[542] R. Kandrotas,et al. Heparin Pharmacokinetics and Pharmacodynamics , 1992, Clinical pharmacokinetics.
[543] S. Wrighton,et al. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.
[544] U. Christians,et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[545] G. Tucker,et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers , 1983, Clinical pharmacology and therapeutics.
[546] A. Fojo,et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. , 1995, British Journal of Cancer.
[547] J. A. Carlston. Drug Interactions and the Cytochrome P-450 Enzymes , 1995 .
[548] I. Kanfer,et al. Pharmacokinetics of Oral Decongestants , 1993, Pharmacotherapy.
[549] T. Blaschke,et al. Clinical pharmacokinetics of rifabutin. , 1996, Clinical pharmacokinetics.
[550] K. Brøsen,et al. Drug Interactions and the Cytochrome P450 System , 1995 .
[551] L. Benet,et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics , 1996, Clinical pharmacology and therapy.
[552] S. Wolfe,et al. Cisapride and torsades de pointes , 1995, The Lancet.
[553] M. Gibaldi,et al. Pharmacogenetics: Part I , 2007 .
[554] F. Guengerich,et al. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[555] G. Tucker,et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. , 1985, British journal of clinical pharmacology.
[556] A. Y. Lu,et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.
[557] C. Alm,et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. , 1994, British journal of clinical pharmacology.
[558] L. Balant. Clinical Pharmacokinetics of Sulphonylurea Hypoglycaemic Drugs , 1981, Clinical pharmacokinetics.
[559] S. Kelly,et al. P450-mediated progesterone hydroxylation in Cochliobolus lunatus , 1995 .
[560] F. Tse,et al. Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.
[561] M. Amici,et al. Identification and full characterization of a new metabolite of metoclopramide , 1996 .
[562] J. Ballinger,et al. The Pharmacokinetics of Thiabendazole and its Metabolites in an Anephric Patient Undergoing Hemodialysis and Hemoperfusion , 1982, Journal of clinical pharmacology.
[563] J. Garrelts,et al. Clofazimine: A Review of its Use in Leprosy and Mycobacterium Avium Complex Infection , 1991, DICP : the annals of pharmacotherapy.
[564] J. Kelly,et al. Clinical Pharmacokinetics of the Newer ACE Inhibitors , 1990, Clinical pharmacokinetics.
[565] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[566] J. Brockmöller,et al. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. , 1995, Journal of hepatology.
[567] C. Alm,et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.
[568] W. Evans,et al. Bleomycin disposition in children with cancer , 1983, Clinical pharmacology and therapeutics.
[569] G. Plosker,et al. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. , 1995, Drugs.
[570] D. Grant,et al. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. , 1995, Pharmacogenetics.
[571] H. Sigusch,et al. Pharmacokinetic interactions of nifedipine and quinidine. , 1995, Die Pharmazie.
[572] R. Skoda,et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.
[573] G. Graham,et al. Salicylate metabolite kinetics after several salicylates , 1981, Clinical pharmacology and therapeutics.
[574] H. Gilles,et al. Studies on the pharmacokinetics of primaquine. , 1981, Bulletin of the World Health Organization.
[575] M. Mathrubutham,et al. Medroxyprogesterone acetate in human serum. , 1981, Journal of steroid biochemistry.
[576] K. Weismann,et al. Pharmacokinetics and Therapeutic Efficacy of Retinoids in Skin Diseases , 1992, Clinical pharmacokinetics.
[577] G. F. Weber,et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.
[578] M. Mattila,et al. Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents , 1994, Clinical pharmacokinetics.
[579] P. Lønning,et al. Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer , 1992, Clinical pharmacokinetics.
[580] D. Greenblatt,et al. Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam , 1988, Journal of clinical pharmacology.
[581] S. Loft,et al. Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. , 1995, Pharmacology & toxicology.
[582] U. Christians,et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. , 1996, British journal of clinical pharmacology.
[583] I. Yamamoto,et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. , 1995, Biological & pharmaceutical bulletin.
[584] I. Bygbjerg,et al. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S‐mephenytoin oxidation in Tanzanians , 1996, Clinical pharmacology and therapeutics.
[585] G. Tucker,et al. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. , 1985, British journal of clinical pharmacology.
[586] A. Li,et al. Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.
[587] E. Acosta,et al. Clinical Pharmacokinetics of Zidovudine , 1996, Clinical pharmacokinetics.
[588] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[589] J. Berman,et al. Pharmacokinetic Justification of Antiprotozoal Therapy , 1991, Clinical pharmacokinetics.
[590] R. Foster,et al. The Nifedipine Gastrointestinal Therapeutic System (GITS) , 2012, Clinical pharmacokinetics.
[591] L. Bertilsson,et al. Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.
[592] K. Hamunen,et al. Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children , 1995, Clinical pharmacokinetics.
[593] Y. Funae,et al. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[594] L. Wienkers,et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[595] P. Beaune,et al. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. , 1993, The Journal of pharmacology and experimental therapeutics.
[596] D. Greenblatt,et al. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.
[597] J. Gallo,et al. Zalcitabine. Clinical pharmacokinetics and efficacy. , 1995, Clinical pharmacokinetics.